Therapeutic management of hyperlipoproteinemia (a)
Cardiovascular disease (CVD) has consistently been the leading cause of death worldwide. Several clinical and epidemiological studies have demonstrated that an elevated plasma concentration of lipoprotein (a) [Lp(a)] is a causative and independent major risk factor for the development of CVD, as wel...
Saved in:
Main Authors: | Constantine E Kosmas (Author), Andreas Sourlas (Author), Gordon Mallarkey (Author), Delia Silverio (Author), Domingo Y Ynoa (Author), Peter D Montan (Author), Eliscer Guzman (Author), Mario J Garcia (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
by: Constantine E Kosmas, et al.
Published: (2018) -
Primary genetic disorders affecting high density lipoprotein (HDL)
by: Constantine E Kosmas, et al.
Published: (2018) -
High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
by: Constantine E Kosmas, et al.
Published: (2018) -
New and emerging lipid-modifying drugs to lower LDL cholesterol
by: Constantine E Kosmas, et al.
Published: (2021) -
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
by: Constantine E Kosmas, et al.
Published: (2017)